Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management
University of Kansas Medical Center
62 participants
Jul 11, 2024
INTERVENTIONAL
Conditions
Summary
Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.
Eligibility
Inclusion Criteria5
- English or Spanish speaking
- Flame or scald burn injury
- \<=10% total body surface area (TBSA) partial thickness
- \<= 5% total body surface area (TBSA) deep partial or full thickness
- Skin graft harvested at 1/12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area
Exclusion Criteria11
- \>10% total body surface area (TBSA) partial thickness burn
- \>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury)
- Traumatic or chemical burn mechanism
- Patients on immunosuppression
- Uncontrolled diabetes
- Known diagnosis of peripheral vascular disease or diagnosis at time of injury
- Pregnant women
- Patients with acquired defective color vision
- Patients with subarachnoid hemorrhage
- Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid
- Inability to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
The wound base is then sprayed with a film of Thrombin-JMI
Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06379724